Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Apr;63(4):484–488. doi: 10.1038/bjc.1991.116

Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

K H Wong 1, C J Koch 1, C A Wallen 1, K T Wheeler 1
PMCID: PMC1972348  PMID: 2021530

Abstract

The acute toxicity, pharmacokinetics and hypoxic cytotoxicity of RSU-1069 were investigated using the subcutaneous (sc) rat 9L tumour model. The pharmacokinetics were studied after i.p. injection of RSU-1069 (20 mg kg-1 or 100 mg kg-1). For both doses, the elimination of RSU-1069 followed first-order kinetics in both plasma and unclamped tumours. After 100 mg kg-1, the peak plasma concentration of RSU-1069 was 40 micrograms ml-1; the elimination t1/2 was 39.3 +/- 11.1 min. After 20 mg kg-1, the peak plasma concentration was 3 micrograms ml-1; the elimination t1/2 was 47.8 +/- 6.3 min. In unclamped tumours, the peak concentration was 50 micrograms g-1 with an elimination t1/2 of 36.1 +/- 9.6 min for the 100 mg kg-1 dose, and 4 micrograms g-1 with an elimination t1/2 of 41.9 +/- 6.1 min for the 20 mg kg-1 dose. The tumour and plasma elimination half-times were not significantly different (P greater than 0.2) for the two doses. Clamping the tumour 30 min after administration of 100 mg kg-1 of RSU-1069 decreased the tumour elimination t1/2 to 10.9 +/- 1.4 min. After releasing the clamp, RSU-1069 returned rapidly to the unclamped tumour concentration. The unclamped tumour/plasma ratio reached a maximum of 4-6, then decreased to a constant value of about 2 for both doses, indicating that RSU-1069 accumulates in these 9L tumours. RSU-1069 kills hypoxic sc 9L cells more efficiently than oxic sc 9L cells; at a surviving fraction of 0.5, the SER was 4.8. For in vitro 9L cells, the SER was approximately 50 when the comparison was between those treated in 2.1% 0(2) and those treated in less than 7.5 x 10(-3)% 0(2); it was approximately 100 when the comparison was between those treated in 21% 0(2) and those treated in less than 7.5 x 10(-3)% 0(3). Tumours treated with RSU-1069 and clamped for various times exhibited biphasic cell-kill kinetics; at 50 mg kg-1, little additional cell kill was achieved after 40 min of clamping. Our data also indicate that RSU-1069 is 300-1000 fold more efficient than misonidazole or SR2508 for killing hypoxic sc 9L tumour cells in situ.

Full text

PDF
484

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Ahmed I., Sheldon P. W., Stratford I. J. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1653–1656. doi: 10.1016/0360-3016(84)90521-2. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Stratford I. J., Wallace R. G., Wardman P., Watts M. E. Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential. J Natl Cancer Inst. 1980 Mar;64(3):555–560. [PubMed] [Google Scholar]
  3. Ahmed I., Jenkins T. C., Walling J. M., Stratford I. J., Sheldon P. W., Adams G. E., Fielden E. M. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1079–1081. doi: 10.1016/0360-3016(86)90230-0. [DOI] [PubMed] [Google Scholar]
  4. Bremner J. C., Stratford I. J., Bowler J., Adams G. E. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990 May;61(5):717–721. doi: 10.1038/bjc.1990.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown J. M. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):675–682. doi: 10.1016/0360-3016(82)90711-8. [DOI] [PubMed] [Google Scholar]
  6. Chaplin D. J., Durand R. E., Stratford I. J., Jenkins T. C. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1091–1095. doi: 10.1016/0360-3016(86)90233-6. [DOI] [PubMed] [Google Scholar]
  7. Clarke E. D., Wardman P., Goulding K. H. Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase. Biochem Pharmacol. 1980 Oct 1;29(19):2684–2687. doi: 10.1016/0006-2952(80)90087-8. [DOI] [PubMed] [Google Scholar]
  8. Cole S., Stratford I. J., Adams G. E. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069. Int J Radiat Biol. 1989 Nov;56(5):587–591. doi: 10.1080/09553008914551781. [DOI] [PubMed] [Google Scholar]
  9. Deacon J. M., Holliday S. B., Ahmed I., Jenkins T. C. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1087–1090. doi: 10.1016/0360-3016(86)90232-4. [DOI] [PubMed] [Google Scholar]
  10. Horwich A., Holliday S. B., Deacon J. M., Peckham M. J. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. Br J Radiol. 1986 Dec;59(708):1238–1240. doi: 10.1259/0007-1285-59-708-1238. [DOI] [PubMed] [Google Scholar]
  11. Keohane A., Godden J., Stratford I. J., Adams G. E. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br J Cancer. 1990 May;61(5):722–726. doi: 10.1038/bjc.1990.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Koch C. J. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat Res. 1984 Feb;97(2):434–442. [PubMed] [Google Scholar]
  13. Koch C. J., Painter R. B. The effect of extreme hypoxia on the repair of DNA single-strand breaks in mammalian cells. Radiat Res. 1975 Nov;64(2):256–269. [PubMed] [Google Scholar]
  14. Koch C. J., Stobbe C. C., Bump E. A. The effect on the Km for radiosensitization at 0 degree C of thiol depletion by diethylmaleate pretreatment: quantitative differences found using the radiation sensitizing agent misonidazole or oxygen. Radiat Res. 1984 Apr;98(1):141–153. [PubMed] [Google Scholar]
  15. Olive P. L., Durand R. E., Chaplin D. J. Cytotoxicity of RSU 1069 in spheroids and murine tumors. Int J Radiat Oncol Biol Phys. 1987 Sep;13(9):1361–1366. doi: 10.1016/0360-3016(87)90230-6. [DOI] [PubMed] [Google Scholar]
  16. Rosenblum M. L., Knebel K. D., Vasquez D. A., Wilson C. B. In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy. Cancer Res. 1976 Oct;36(10):3718–3725. [PubMed] [Google Scholar]
  17. Siemann D. W., Alliet K., Maddison K., Wolf K. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069. Cancer Treat Rep. 1985 Dec;69(12):1409–1414. [PubMed] [Google Scholar]
  18. Siemann D. W. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1115–1118. doi: 10.1016/0360-3016(89)90929-2. [DOI] [PubMed] [Google Scholar]
  19. Stratford I. J., Walling J. M., Silver A. R. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer. 1986 Mar;53(3):339–344. doi: 10.1038/bjc.1986.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wallen C. A., Michaelson S. M., Wheeler K. T. Evidence for an unconventional radiosensitivity of rat 9L subcutaneous tumors. Radiat Res. 1980 Dec;84(3):529–541. [PubMed] [Google Scholar]
  21. Walling J. M., Deacon J., Holliday S., Stratford I. J. High uptake of RSU 1069 and its analogues melanotic melanomas. Cancer Chemother Pharmacol. 1989;24(1):28–32. doi: 10.1007/BF00254101. [DOI] [PubMed] [Google Scholar]
  22. Walton M. I., Workman P. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. Cancer Chemother Pharmacol. 1988;22(4):275–281. doi: 10.1007/BF00254231. [DOI] [PubMed] [Google Scholar]
  23. Wheeler K. T., Wallen C. A., Wolf K. L., Siemann D. W. Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole. Br J Cancer. 1984 Jun;49(6):787–793. doi: 10.1038/bjc.1984.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Whitmore G. F., Gulyas S. Studies on the toxicity of RSU-1069. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1219–1222. doi: 10.1016/0360-3016(86)90262-2. [DOI] [PubMed] [Google Scholar]
  25. Wilson A. P., Ford C. H., Newman C. E., Howell A. A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. Br J Cancer. 1984 Jan;49(1):57–63. doi: 10.1038/bjc.1984.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wong K. H., Wallen C. A., Wheeler K. T. Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):135–143. doi: 10.1016/0360-3016(89)90381-7. [DOI] [PubMed] [Google Scholar]
  27. Wong K. H., Wallen C. A., Wheeler K. T. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. Int J Radiat Oncol Biol Phys. 1990 May;18(5):1043–1050. doi: 10.1016/0360-3016(90)90439-q. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES